Month: April 2017

DENKI KAGAKU KOGYO KABUSHIKI KAISHA (Head­quar­tered at: Chuo-ku, Tokyo; Shin­suke Yoshi­ta­ka, Pres­i­dent & CEO, here­inafter ”Den­ka”) is pleased to announce that, it has agreed and entered into a share trans­fer agree­ment on August 6, 2015 with Nomad Bio­science GmbH (Head­quar­tered at: Munich, Ger­many; Prof. Dr. Yuri Gle­ba, CEO, here­inafter ”Nomad”) regard­ing its acqui­si­tion (the ”Acqui­si­tion”)… Read more »

Icon Genet­ics GmbH (ICON) suc­cess­ful­ly com­plet­ed a Phase I clin­i­cal study on the safe­ty and immuno­genic­i­ty of per­son­al­ized vac­cines to treat patients with fol­lic­u­lar non-Hodgkin’s lym­phoma. The vac­cines, which con­sist of mon­o­clon­al anti­bod­ies derived from each patient’s own tumor and serve as dis­­ease-spe­­cif­ic mark­ers, were admin­is­tered to induce a tumor-spe­­cif­ic immune reac­tion. The vac­cines were… Read more »

Icon Genet­ics GmbH, Munich, Ger­many (ICON) and Bay­er Crop­Science have suc­cess­ful­ly cre­at­ed a nov­el plant host sys­tem for the pro­duc­tion of bio­phar­ma­ceu­ti­cals. Bay­er has deliv­ered a Nico­tiana plant that is defi­cient in plant-spe­­cif­ic sug­ar residues result­ing in dif­fer­ent plant gly­co­sy­la­tion pat­terns. The plant host is already being used by ICON as a new com­po­nent in… Read more »

A three-part doc­u­men­tary series with par­tic­i­pa­tion of patients involved in Phase I clin­i­cal tri­als of Icon’s Non-Hodgkin’s Lym­phoma per­son­al­ized vac­cine was recent­ly released for pub­lic view. Full doc­u­men­tary can be seen at http://www.baylorhealth.com/dallashope/pages/default.aspx.

Munich, Sep­tem­ber 20, 2012 — Icon Genet­ics GmbH (ICON), Munich/Halle, Ger­many, has announced that the Com­pa­ny has entered into a license agree­ment with the Sains­bury Lab­o­ra­to­ry (TSL) and the John Innes Cen­tre (JIC), Nor­wich, UK, that allows TSL and JIC to use in its research ICON’s high-through­put DNA Assem­bly Plat­form known as ‘Gold­en Gate Cloning’.… Read more »

Johan­nes­burg, 16 July 2012 — The Coun­cil for Sci­en­tif­ic and Indus­tri­al Research and ICON, Munich/Halle, Ger­many, have announced that they have entered into an agree­ment that will allow the CSIR to make use of its plant-based man­u­fac­tur­ing plat­form known as ‘mag­nI­CON®’ for research and devel­op­ment (R&D) and roy­al­­ty-free man­u­fac­tur­ing of rabies vac­cines and post-expo­­sure pro­phy­lax­is… Read more »

Icon Genet­ics GmbH (ICON), Munich/Halle, Ger­many, a plant biotech­nol­o­gy com­pa­ny, has announced that the Com­pa­ny has been award­ed a pres­ti­gious Frost & Sul­li­van Euro­pean Tech­nol­o­gy Inno­va­tion Award. For the Tech­nol­o­gy Inno­va­tion Award, the fol­low­ing cri­te­ria were used to bench­mark Icon Genet­ics’ per­for­mance against key com­peti­tors: unique­ness of the tech­nol­o­gy; impact on new products/applications; impact on… Read more »

Munich, May 09, 2012 — Icon Genet­ics GmbH, Munich, Ger­many (ICON) and Bay­er Crop­Science have entered into a con­tract devel­op­ment agree­ment to cre­ate nov­el plant pro­duc­tion hosts for bio­phar­ma­ceu­ti­cals. The aim of the agree­ment is to devel­op man­u­fac­tur­ing hosts with a design­er gly­co­sy­la­tion, in par­tic­u­lar, human­ized gly­co­sy­la­tion. Such hosts with mod­i­fied gly­co­sy­la­tion of recom­bi­nant pro­teins… Read more »

OWENSBORO, Ken­tucky (USA), SAN DIEGO, Cal­i­for­nia (USA) and MUNICH (Ger­many), May 07, 2012 — Ken­tucky Bio­pro­cess­ing, LLC (KBP), Icon Genet­ics, GmbH (ICON) and Mapp Bio­phar­ma­ceu­ti­cal, Inc. (Mapp­bio) have announced that they have entered into detailed nego­ti­a­tions aimed at merg­ing the com­pa­nies to cre­ate a sin­gle, ful­ly inte­grat­ed bio­phar­ma­ceu­ti­cal dis­cov­ery, devel­op­ment and man­u­fac­tur­ing enter­prise. While many… Read more »